Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 11/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 11/20 | 0.59 |
| ▸ | FAP | Q12884 | 9/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.53 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3741726 | 0.99 | DPP4 (0.58) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8088377 | 0.85 | DPP4 (0.58) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8090561 | 0.84 | DPP4 (0.54) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL13078719 | 0.83 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL13045329 | 0.83 | DPP4 (0.55) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL8088530 | 0.83 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| Trifluoroacetic Acid SCHEMBL3744761 | 0.82 | DPP4 (0.57) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL3744760 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9FAPDPP7 | |
| Trifluoroacetic Acid SCHEMBL3742063 | 0.81 | DPP4 (0.51) | DPP4ELOVL6 | |
| Trifluoroacetic Acid SCHEMBL3738343 | 0.80 | DPP4 (0.58) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.